Oral Answers to Questions

Debate between Robert Jenrick and Vicky Foxcroft

Monday 27th November 2023 Commons Chamber

[Vicky Foxcroft (Lewisham, Deptford) (Lab)]

T2. Many of my constituents have faced significant delays when applying for biometric residence permit cards because of technical errors. One constituent, whose application was approved in July 2020, did not receive their BRP until January 2023 because of printing issues. What actions are being taken to address the technical problems contributing to delays in processing BRP applications? I hope the Home Secretary can answer that question.

[The Minister for Immigration (Robert Jenrick)]

I am pleased to report to the hon. Lady that that part of our Visas and Immigration service is now operating within its service standard, so there is a good service being offered to members of the public, but if she has any specific cases, she can bring them to my attention.

Oral Answers to Questions

Debate between Robert Jenrick and Vicky Foxcroft

Monday 22nd May 2023 Commons Chamber

[Robert Jenrick]

I know how strongly my hon. Friend feels about this issue. I will of course look into those contracts, but the enduring solution to this issue is to stop the boats in the first place. That is why we brought forward the Illegal Migration Bill.

[Vicky Foxcroft (Lewisham, Deptford) (Lab)]

T3. Members of Turning Point UK have protested three times in my constituency in recent months, attempting without success to spread hatred and division in our community. Does the Home Secretary have any concerns about this organisation and how it receives its funding?

Oral Answers to Questions

Debate between Robert Jenrick and Vicky Foxcroft

Monday 6th February 2023 Commons Chamber

[Robert Jenrick]

We provide funding for every asylum seeker who is in a local authority’s care of about £3,500, and we work closely with local authorities through the mandatory dispersal system to make sure that each one plays a fair and equitable part. However, the answer to this problem is not more accommodation; it is stopping the boats and ensuring that we have some of the most robust laws in the world, so that those who come here illegally do not find a way to a life in the UK. I hope that the hon. Lady will support us when we introduce our legislation.

[Vicky Foxcroft]

My constituent arrived here from Syria and claimed asylum in July 2021. He is a doctor and applied to volunteer with the covid vaccination programme, but was turned down because he had no documentation. After more than a year and many interventions by my office, he finally had his asylum interview and was given a job as a healthcare assistant, but that was delayed because he had to wait for his national insurance number. The NHS is crying out for staff. When will the Government sort this out?

[Robert Jenrick]

We are working to bring down the backlog of cases. Let me gently point out that the last Labour Government left a backlog of cases of not 450,000, as I said during the last session of Home Office questions, but 500,000, as has been shown by further research. So bad was the backlog that there was even a room colloquially known as the “room of doom” into which cases were put. We will get the backlog down, and create a streamlined and efficient asylum system.

Oral Answers to Questions

Debate between Robert Jenrick and Vicky Foxcroft

Monday 19th December 2022 Commons Chamber

[Vicky Foxcroft (Lewisham, Deptford) (Lab)]

10. What recent progress her Department has made on reducing the backlog of asylum applications.

[The Minister for Immigration (Robert Jenrick)]

Last week we set out plans to clear the initial decision backlog of asylum legacy cases by the end of next year. Over the summer and autumn, the Home Office reduced the number of older asylum cases by 11,000, and the number of asylum caseworkers has doubled.

[Robert Jenrick]

I would be interested in the views of any of our stakeholders, but the Prime Minister set out a very compelling case last week to radically re-engineer the end-to-end process, with fewer interviews, shorter guidance, less paperwork, specialist caseworkers by nationality, including tackling Albanian cases, and reforming modern slavery by reducing the cooling-off period from 45 to 30 days—all steps to clear the backlog as quickly as possible.

[Vicky Foxcroft]

One of my constituents arrived in the UK from Afghanistan and claimed asylum in September 2021. Despite my caseworkers making regular inquiries since August 2022, we have received no updates regarding the status of his application. He tells us that the situation has made him seriously depressed. Does the Minister agree that excessive wait times can have a hugely detrimental impact on mental health, and will he agree to look at this case in further detail?

[Robert Jenrick]

I would be happy to look at that case and any others that are brought to my attention. The backlog, however, is a symptom of the problem, which is that far too many people are crossing the channel illegally, and that is what this Government are determined to tackle. The hon. Lady and her Opposition colleagues have voted against every tough measure that we have sought to take in recent years. I hope that she will now get behind the measure that we are taking, the statement the Prime Minister made last week and, of course, our world-leading Rwanda partnership, which the Court today gave its agreement to.

Procurement of Evusheld

Debate between Robert Jenrick and Vicky Foxcroft

Wednesday 12th October 2022 Westminster Hall

[Robert Jenrick]

I am grateful to the hon. Member for that comment. Given the urgent need—we all agree on that—to protect lives during the pandemic, we also expedited processes by creating RAPID C-19 as a multi-agency initiative made up of the UK’s main healthcare agencies. It was established in 2020, in response to the pandemic, to get treatments, such as Evusheld, to NHS patients quickly and safely. Therefore we did not simply leave the matter in the hands of NICE; we asked RAPID C-19 to review the evidence base for the use of Evusheld and to consider whether the evidence merited patients having access to it ahead of the normal NICE appraisal. The evidence has now been published and is available on gov.uk; any emerging evidence will continue to be kept under review. That includes the Crick data that the hon. Member for St Albans mentioned, which was published in May and in August and is now being reviewed by RAPID C-19, and also the Lancet study that she referenced, which was published on 6 October, relatively recently.

Three types of evidence have been considered. The clinical trial data is generally the strongest source of evidence. However, in this case, the trial was carried out before omicron became dominant, so it does not confirm efficacy for omicron variants. It would be, I think, concerning to deploy a drug on the NHS that had not been considered in the light of omicron.

[Vicky Foxcroft (Lewisham, Deptford) (Lab)]

Will the Minister give way?

[Robert Jenrick]

I will, but given that I have only five minutes remaining to me, this is the last time I will be able to take an intervention.

[Vicky Foxcroft]

The Minister is making an interesting speech, but I am really inquisitive as to how we are still using vaccines that have not been tested on omicron, yet we are using the excuse of Evusheld not being tested on omicron for those people who are immunocompromised.

[Robert Jenrick]

Before we deploy Evusheld on the NHS and give members of the public the sense of security that comes with that, it is clearly sensible for us to investigate its efficacy in the light of the dominant variant. Otherwise, we would be giving people a false sense of security.

We have looked at in vitro neutralisation studies, which can be completed much more rapidly than clinical trials, that have measured in the lab how a new variant changes the binding efficacy of the therapeutic. These studies show reduced binding with different omicron variants, which means that the clinical efficacy against these variants is expected to be reduced. We have also reviewed the published clinical experience of the use of Evusheld, including the studies emerging from the United States and Israel. There can be difficulties in interpreting some observational studies if, for example, there is not an appropriate control group. The conclusion of the evidence review is that there are uncertainties about efficacy, so a clinical trial has been proposed to look at that. We are working with AstraZeneca on the practicalities of creating an urgent trial that can inform the debate ahead of NICE’s ultimate decision in early 2023.

As was noted, other countries have introduced Evusheld, including, in some cases, before omicron was dominant. Many have decided to double the dose to try to counter the drug’s reduced ability to neutralise the omicron variant. Our experts consider that even at this increased dose, the evidence is still insufficient to demonstrate efficacy, so individuals could be at risk if they changed the protective behaviours that they have undertaken for many months.

The Government recognise that an effective pre-exposure programme for immunosuppressed people would be valuable, but the scientific evidence does not support emergency deployment of Evusheld at this time. To boost the evidence base for future decisions, clinical advisers in the expert groups and my Department have recommended a clinical trial, which could help us to answer outstanding questions on dose, efficacy and duration of protection against different variants. We are working through the practicalities of that trial. We will update colleagues and members of the public as quickly as possible.

We have had great success in generating evidence in clinical trials; last week, initial results from the PANORAMIC trial indicated that early treatment with one drug significantly reduced recovery time, and we will now work in the same way to understand what this evidence means for patient access to the drug. I appreciate the difficulties that immunosuppressed individuals face, particularly if they are concerned about not having protection from covid-19 vaccinations, and so continue with behaviours to avoid covid-19. We all recognise the impact that that has on individuals’ lives and want to improve their quality of life. The Antivirals and Therapeutics Taskforce has ensured that UK patients have the earliest access to antiviral, antibody and anti-inflammatory COVID-19 treatments. NHS patients were often the first in the world to receive safe and effective treatment, both in clinical trials and following regulatory approval of treatments.

Colleagues here and those listening at home have my personal assurance that I will continue to work with expert advisers in the Department, and with RAPID C-19, to ensure that they review all emerging evidence, and to ensure that the NICE process is carried out as swiftly as possible, while ensuring that it is safe and efficacious; we want to ensure that members of the public, who may ultimately receive this drug, have confidence that it does what they think it does.

I am holding a meeting for Members of this House with our expert advisers tomorrow at 11 am. It will give Members the opportunity to ask our experts, including those who have been part of RAPID C-19, any questions and seek further assurances. I am grateful to the hon. Member for St Albans for securing this debate, and for the passionate way in which she expressed the strong feelings of members of the public; I hope to work with her productively in the months ahead.

Question put and agreed to.

Oral Answers to Questions

Debate between Robert Jenrick and Vicky Foxcroft

Monday 19th July 2021 Commons Chamber

[Vicky Foxcroft (Lewisham, Deptford) (Lab) [V]]

Many of the buildings in my constituency that have been found to have cladding defects, including Norfolk House, St Peters Gardens and Leeward Court, are under 18 metres and therefore ineligible for the building safety fund. The only offer made to impacted leaseholders is a loan scheme, with no clarity about how it will work and when it will be made available. When will the Secretary of State’s Department finally step up and extend funding to those blocks under 18 metres that are in need of remediation?

[Robert Jenrick]

In terms of buildings with the most dangerous form of cladding, there are five that I am aware of in Lewisham. One has completed work and is awaiting building control sign-off, three have had their unsafe aluminium composite material cladding removed altogether, and the other one has works under way, so we are making good progress there, as we are elsewhere in the country. On buildings below 18 metres, we need to take a more proportionate approach. There are leaseholders who are being asked to pay bills for those buildings that are unconscionable and likely to be unnecessary. I am working intensively with lenders, insurers and building safety experts to change that, because we have to adopt a more proportionate and sensible regime than the one we are experiencing right now.

Oral Answers to Questions

Debate between Robert Jenrick and Vicky Foxcroft

Tuesday 11th September 2018 Commons Chamber

[Robert Jenrick]

As the hon. Lady will be aware, the Arts Council has a formula to distribute funding across the country. We believe, like she does, that it is important that all communities in this country can have access to culture and heritage. It is for that reason and others that we funded the Great Exhibition of the North, which has been a huge success; and of course the Chancellor, in his Budget two years ago, supported the huge economic and cultural opportunity of restoring Wentworth Woodhouse, near to the hon. Lady’s constituency.

[Vicky Foxcroft (Lewisham, Deptford) (Lab)]

8. Whether he has made an assessment of the adequacy of his Department's cross-departmental guidance on the contracting out of public services as a result of recent disturbances in prisons.